Clinical trials: Hepatitis C Virus (HCV)
Chronic Hepatitis C
CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) Subjects
To explore the effect on early viral kinetics and viral load, and to determine safety, tolerability and anti-viral response for the plasmid DNA vaccine CHRONVAC-C administered i.m.
- Trial name
- NCT01335711
- Testing
- ChronVac-C + SOC, SOC
- Where
- 2 sites in Sweden
- Volunteers
- 32 people
- Sponsor
- ChronTech Pharma AB
Hepatitis C, Chronic
A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection
The objective of the study is to evaluate the safety and efficacy of celgosivir for 12 weeks in patients with chronic hepatitis C genotype 1 infection.
- Trial name
- NCT00157534
- Testing
- Celgosivir
- Volunteers
- 43 people
- Sponsor
- BioWest Therapeutics Inc
Hepatitis C
The Boceprevir and Sildenafil Pharmacokinetics Study
This is a healthy volunteer study looking at the interactions between two drugs: boceprevir and sildenafil. New drugs are being developed to treat people with the chronic viral infection hepatitis C.
- Trial name
- NCT01499498
- Testing
- Sildenafil and Boceprevir
- Where
- United Kingdom
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Hepatitis C, Substance Use Disorders
HCV Group Evaluation and Treatment Uptake (HCV GET-UP) Intervention
People who inject drugs (PWID) represent the overwhelming majority of both HCV and HIV/HCV infected people in the United States.
- Trial name
- NCT03242655
- Testing
- HCV GET-Up (Group Evaluation and Treatment Uptake)
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Liver Cancer, Hepatitis B
Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocellular Carcinoma
Adult liver cancer is the third leading cause of cancer deaths worldwide. The major risk factor for liver cancer is hepatitis B virus (HBV) infection.
- Conditions
- Liver Cancer, Hepatitis B, Hepatitis C, Hepatobiliary Cancers Liver
- Trial name
- NCT00767936
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Stanford University
Hepatitis C Virus (HCV)
Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver Cirrhosis
Hepatitis C Virus (HCV) infection is among the most common of all chronic liver diseases. HCV predominantly affects liver cells and causes the liver to become inflamed and damaged.
- Trial name
- EASY (NCT04352309)
- Where
- 6 sites in Russia
- Volunteers
- 99 people
- Sponsor
- AbbVie
Investigate the Renal Effect of DAAs on Egyption Patients After Completion of Treatment
Prevalence of Kidney Injury in Patients With HCV Treated With Sofuspovir Containing DAA Therapy
this study aims is to investigate the occurrence of AKI during antiviral therapy, defined as an increase of 0.3 mg/dL or 50% at least in serum creatinine level when compared with baseline values or more than a 25% reduction in…
- Trial name
- NCT04267458
- Testing
- evaluation of sofuspovir containing DAA regien expected insult on kidney
- Where
- Egypt
- Volunteers
- 300 people
- Sponsor
- Cairo University
Chronic Hepatitis C Infection, HCV Genotype 1b
Clinical Investigation of Erlotinib as an HCV Entry Inhibitor
Chronic Hepatitis C Virus (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma world-wide. Current combination therapy of pegylated interferon-alfa, ribavirin and protease inhibitors is limited by…
- Trial name
- NCT01835938
- Testing
- 1- Erlotinib
- Where
- France
- Volunteers
- 12 people
- Sponsor
- University Hospital, Strasbourg, France
Hepatitis C, Chronic
Rapid HCV RNA Testing and LInkage to Care
The investigators propose to conduct a pilot randomized controlled trial comparing treatment as usual (TaU) for HCV screening (rapid anti-HCV screening and referral) to a intervention screening that includes TaU plus a rapid…
- Trial name
- TEAL (NCT04302948)
- Testing
- HCV RNA screening
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of New Mexico
Hepatitis C
Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients
The purpose of this study is to determine whether 24 week treatment with the Daclatasvir (DCV) in combination with Pegylated-interferon alfa 2a (pegIFNα-2a) and Ribavirin (RBV) is safe and demonstrates rate of Sustained Virologic…
- Trial name
- COMMAND-Asia (NCT01797848)
- Testing
- Peginterferon alfa 2a, Ribavirin, Daclatasvir
- Sponsor
- Bristol-Myers Squibb
HIV Prevention, Sexually Transmitted Infections (STI)
California MEPS Hub
The California Hub for HIV/SUD Prevention Research with Reentry Populations addresses the question: "Can the evidence-based MEPS intervention be adapted and implemented at a range of organizations to effectively serve a wider…
- Conditions
- HIV Prevention, Sexually Transmitted Infections (STI), Preexposure Prophylaxis (PrEP), Incarceration
- Trial name
- NCT07433985
- Testing
- Mobile Enhanced Prevention Support (MEPS), Control
- Where
- 3 sites in United States
- Volunteers
- 318 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Hepatitis C
Hepatitis C Patient Management and Family Health Education
INTRODUCTION: Hepatitis C virus (HCV) is recognized as the leading cause of chronic liver disease worldwide. However, the screening rate and treatment rate of HCV-infected patients in China is low, which increases the burden of…
- Trial name
- NCT03813498
- Testing
- HCV articles, general health articles
- Volunteers
- 1,000 people
- Sponsor
- China Liver Health
HIV, Hepatitis B
Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests
This is a pilot, monocentric, prospective, randomized control trial looking at the use of rapid tests as a part of normal care. The investigators will be testing for hepatitis B virus (HBV), hepatitis C virus (HCV), and human…
- Conditions
- HIV, Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular
- Trial name
- OPTISCREEN-III (NCT01790633)
- Testing
- ELISA, Rapid Test
- Where
- France
- Volunteers
- 327 people, healthy volunteers welcome
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
HIV Infections, Hepatitis C
Estimation of the Prevalence of HIV, Hepatitis C and Hepatitis B Infection Among Detainees in the Nîmes Administrative Detention Center
People in Administrative Detention Centers often come from areas of medium or high HIV, hepatitis C \& B endemic, and are often unaware of their serological status.
- Conditions
- HIV Infections, Hepatitis C, Hepatitis B
- Trial name
- TRODUMCRA (NCT05127187)
- Testing
- Rapid diagnosis test against HIV and hepatitis C and B
- Where
- France
- Volunteers
- 350 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
HIV, Hepatitis C
Strategic Screening for Infectious Diseases (Tuberculosis, HIV, HBV, HCV) Amongst Migrants in France
To evaluate the efficacy of a new screening for infectious diseases: tuberculosis, HIV, HBV and HCV, based on risk factors questionnaires (TB screen for tuberculosis and TROD screen for HIV and hepatitis) amongst a population of…
- Conditions
- HIV, Hepatitis C, Hepatitis B, Tuberculosis
- Trial name
- STRADA (NCT02959684)
- Where
- 18 sites in France
- Volunteers
- 70,000 people, healthy volunteers welcome
- Sponsor
- University Paris 7 - Denis Diderot
Hepatitis C, Chronic
A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy
In this randomized, cross-over, open label study the correlation of Pegasys (peginterferon alfa-2a) pharmacokinetics after intravenous (iv) and subcutaneous (sc) administration with viral load and viral kinetics will be…
- Trial name
- NCT01337375
- Testing
- peginterferon alfa 2a [Pegasys], peginterferon alfa-2a [Pegasys]
- Where
- 5 sites in Germany
- Volunteers
- 31 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
Evaluation Study of RDTs Detecting Antibodies Against HCV
The study aims to evaluate 13 different HCV RDTs (10 on-market, 3 under development) for their diagnostic performance and operational characteristics in archived EDTA plasma samples, originating from patients from different…
- Trial name
- NCT04033887
- Testing
- 13 Rapid Diagnostic Tests and reference tests
- Where
- 3 sites in Belgium, Georgia and 1 more
- Volunteers
- 1,710 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Liver Transplant
Efficacy and Safety of Basiliximab in Hepatitis C Virus Positive Patients Undergoing Liver Transplantation
The natural history of HCV infection in liver transplant recipients may be accelerated when compared to that in patients with normal immune systems.
- Trial name
- NCT00238901
- Testing
- Basiliximab
- Volunteers
- 194 people
- Sponsor
- Novartis
Hepatitis C
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
The purpose of this research study is to find out the effect of the investigational drug NOV-205 on the level of hepatitis C virus in the blood and whether NOV-205 is well-tolerated at different doses when taken by subjects with…
- Trial name
- NOV-205 (NCT01058512)
- Testing
- NOV-205
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Cellectar Biosciences, Inc.
Hepatitis C
Prevalence of IL28B Polymorphism in Hepatitis C Patients
Response to peginterferon and ribavirin treatment in hepatitis C (HCV) depends on viral and host factors. Single nucleotide polypmorphisms (SNP) near to IL28B gene (especially at rs12979860 and rs8099917) are strongly associated…
- Trial name
- NCT03415009
- Where
- Singapore
- Volunteers
- 39 people
- Sponsor
- Changi General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.